Pathstone Holdings
MRNA icon

Pathstone Holdings’s Moderna MRNA Stock Holding History

Pathstone Holdings’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
20,938
+10
+0% +$517 ﹤0.01% 1305
2026
Q1 		$1.06M Buy
20,928
+13,384
+177% +$624K ﹤0.01% 1378
2025
Q4 		$222K Sell
7,544
-8,590
-53% -$233K ﹤0.01% 2070
2025
Q3 		$417K Sell
16,134
-1,017
-6% -$28.4K ﹤0.01% 1857
2025
Q2 		$473K Sell
17,151
-1,247
-7% -$32.8K ﹤0.01% 1745
2025
Q1 		$522K Buy
18,398
+5,501
+43% +$195K ﹤0.01% 1695
2024
Q4 		$537K Sell
12,897
-2,780
-18% -$133K ﹤0.01% 1691
2024
Q3 		$1.05M Sell
15,677
-6,167
-28% -$566K ﹤0.01% 1348
2024
Q2 		$2.59M Buy
21,844
+3,035
+16% +$384K 0.01% 800
2024
Q1 		$2M Buy
18,809
+3,446
+22% +$347K 0.01% 900
2023
Q4 		$1.53M Buy
+15,363
New +$1.29M 0.01% 843

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Pathstone Holdings's MRNA Position: Q2 2026 in Review

Pathstone Holdings increased its Moderna (MRNA) stake by 0.05% in Q2 2026, buying an estimated $517 and bringing the position to 20,938 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1305.

Pathstone Holdings first reported a position in MRNA in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.59M in Q2 2024. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Pathstone Holdings held 20,938 shares of Moderna worth $1.47M as of Q2 2026.
  • Pathstone Holdings bought 10 Moderna shares in Q2 2026, an estimated $517.
  • Moderna made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #1305 holding.
  • Pathstone Holdings first reported a position in Moderna in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's Moderna position peaked at $2.59M in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.